PharmAsia News Presents: Notable Notes On Emerging Markets (Vol. 1, No. 2)
This article was originally published in PharmAsia News
Executive Summary
In this periodic feature, PharmAsia News highlights recent analyst notes with a unique viewpoint on Asia or other emerging markets. The previous issue appeared in PharmAsia News, June 14, 2011.
You may also be interested in...
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.